kabutan

ZERIA PHARMA, 7% Decrease in Ordinary Profit for The Current Fiscal Year, Increased Previous Year's Dividend by 1 yen, This Fiscal Year to Increase Dividend by 1 yen

Thu May 8, 2025 4:00 pm JST Earnings

4559 ZERIA PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

ZERIA PHARMACEUTICAL CO.,LTD. <4559> [TSE Prime] announced its financial results after the market closed on May 8th (16:00). The consolidated ordinary profit for the fiscal year ending March 2025 expanded 50.8% from the previous period to 12.8 billion yen. However, for the fiscal year ending March 2026, the consolidated ordinary profit is expected to decrease by 6.5% from the previous period to 12 billion yen.

At the same time, the company increased the annual dividend for the previous term from 46 yen to 47 yen (compared to 44 yen in the prior term), and has decided to increase the dividend this fiscal year to 48 yen, an increase of 1 yen from the previous fiscal year.

In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit/loss turned to a profit of 2.17 billion yen (compared to a loss of 0.93 billion yen in the same period last year). The operating profit margin drastically improved from 0.7% in the same period last year to 8.7%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 68,383 9,014 7,579 6,195 140.3 40 May 11, 2023 J-GAAP
Mar, 2024 75,725 9,621 8,513 7,731 175.4 44 May 9, 2024 J-GAAP
Mar, 2025 87,311 12,197 12,840 9,936 225.4 47 May 8, 2025 J-GAAP
YoY +15.3% +26.8% +50.8% +28.5% +28.5%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 86,500 12,000 12,000 9,000 204.2 46 Feb 5, 2025 J-GAAP
Mar, 2025 Results 87,311 12,197 12,840 9,936 225.4 47 May 8, 2025 J-GAAP
Revision Rate +0.9% +1.6% +7.0% +10.4% +10.4%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 42,422 6,459 7,949 6,061 137.5 23 Nov 6, 2024 J-GAAP
Apr - Sep, 2025 Guidance 43,000 5,000 5,000 4,000 90.8 24 May 8, 2025 J-GAAP
YoY +1.4% -22.6% -37.1% -34.0% -34.0%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 75,725 9,621 8,513 7,731 175.4 44 May 9, 2024 J-GAAP
Mar, 2025 87,311 12,197 12,840 9,936 225.4 47 May 8, 2025 J-GAAP
Mar, 2026 Guidance 90,000 12,000 12,000 9,500 215.5 48 May 8, 2025 J-GAAP
YoY +3.1% -1.6% -6.5% -4.4% -4.4%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 17,806 131 -931 -692 -15.7 0.7 May 9, 2024 J-GAAP
Apr - Jun, 2024 21,455 3,939 5,459 4,212 95.6 18.4 Aug 1, 2024 J-GAAP
Jul - Sep, 2024 20,967 2,520 2,490 1,849 42.0 12.0 Nov 6, 2024 J-GAAP
Oct - Dec, 2024 22,351 3,787 2,712 2,165 49.1 16.9 Feb 5, 2025 J-GAAP
Jan - Mar, 2025 22,538 1,951 2,179 1,710 38.8 8.7 May 8, 2025 J-GAAP
YoY +26.6% +1,389.3% － － －

Related Articles